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Helicobacter pylori Infection Is
AssociatedWith an Increased Rate
of Diabetes
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OBJECTIVEdChronic infections could be contributing to the socioeconomic gradient in
chronic diseases. Although chronic infections have been associated with increased levels of in-
flammatory cytokines and cardiovascular disease, there is limited evidence on how infections
affect risk of diabetes.
RESEARCH DESIGN AND METHODSdWe examined the association between sero-
logical evidence of chronic viral and bacterial infections and incident diabetes in a prospective
cohort of Latino elderly. We analyzed data on 782 individuals aged.60 years and diabetes-free
in 1998–1999, whose blood was tested for antibodies to herpes simplex virus 1, varicella virus,
cytomegalovirus, Helicobacter pylori, and Toxoplasma gondii and who were followed until June
2008. We used Cox proportional hazards regression to estimate the relative incidence rate of
diabetes by serostatus, with adjustment for age, sex, education, cardiovascular disease, smoking,
and cholesterol levels.
RESULTSdIndividuals seropositive for herpes simplex virus 1, varicella virus, cytomegalovi-
rus, and T. gondii did not show an increased rate of diabetes, whereas those whowere seropositive
for H. pylori at enrollment were 2.7 times more likely at any given time to develop diabetes than
seronegative individuals (hazard ratio 2.69 [95% CI 1.10–6.60]). Controlling for insulin resis-
tance, C-reactive protein and interleukin-6 did not attenuate the effect of H. pylori infection.
CONCLUSIONSdWe demonstrated for the first time that H. pylori infection leads to an
increased rate of incident diabetes in a prospective cohort study. Our findings implicate a po-
tential role for antibiotic and gastrointestinal treatment in preventing diabetes.
Diabetes Care 35:520–525, 2012
Cardiovascular diseases and diabetesdisproportionately affect people oflow socioeconomic status and mi-
nority race in the U.S. (1). Behavioral risk
factors, such as poor diet, smoking, and
physical inactivity, are well-known con-
tributors to the disparity, but only par-
tially explain the gap in health states
(2,3). Other contributing factors may in-
clude chronic infections that are more
prevalent among minorities and individ-
uals of low-socioeconomic status (4). In
fact, studies suggest that pathogen burden,
including infectious agents, such as cyto-
megalovirus, herpes simplex virus (HSV),
Chlamydia pneumoniae, and Helicobacter
pylori, may have an impact on cardiovas-
cular conditions andmetabolic syndrome
(5–7) potentially mediated by elevations in
inflammatory markers such as C-reactive
protein (CRP) and interleukin (IL)-6 (5).
Inflammation and activated innate immu-
nity have also been implicated in the patho-
genesis of diabetes through insulin
resistance (8). For example, elevated levels
of inflammatory cytokines may lead to
phosphorylation of serine residues on the
insulin receptor substrate, which prevents
its interactionwith insulin receptors, inhib-
iting insulin action (8). Lipopolysacchar-
ides from pathogens in the gut, such as H.
pylori, have also been linked to the activa-
tion of Toll-like receptors, resulting in en-
ergy harvesting, fat accumulation and
stimulation of the innate immune system,
and consequent insulin resistance (9).
However, epidemiological studies investi-
gating the impact of pathogen burden on
diabetes have been limited. A previous
study found increased risk of diabetes in
people with a high burden of periodontal
bacteria (10). On the other hand, cross-
sectional studies examining other more
systemic pathogens and insulin resis-
tance or prevalent diabetes have pro-
duced equivocal findings (11–13), with
higher titers of antibodies to HSV2 and
C. pneumoniae showing decreased insulin
sensitivity in one study (11) and infection
with C. pneumoniae, H. pylori, cytomega-
lovirus, HSV, and/or hepatitis A showing
no association with insulin resistance or
prevalent diabetes in other studies
(12,13). These earlier studies were limited
by cross-sectional analyses, and there are
no prospective studies, of which we are
aware, to elucidate whether there is a po-
tential causal relationshipbetweendifferent
types of pathogens or pathogen burden and
incident diabetes. In addition, there has
been a lack of epidemiological studies ex-
amining the potential pathways by which
pathogens may affect diabetes, such as in-
flammation. In this study, we aim to exam-
ine the effects of specific pathogens and
pathogen burden, as measured by sero-
positivity to five pathogensdHSV1, vari-
cella virus (VZV), cytomegalovirus (CMV),
Toxoplasma gondii, and H. pyloridon inci-
dent diabetes over 10 years and whether
these relationships are mediated by in-
flammation and insulin resistance. We
selected HSV1, CMV, and H. pylori be-
cause they have previously been investi-
gated with regard to pathogen burden
and diabetes or cardiovascular disease.
Among other pathogens for which data
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were available, we also included VZV,
since it is a herpes virus closely related
to HSV1 and CMV, as well as T. gondii,
since it has been associated with other
chronic conditions, including neuropa-
thy and cognitive function.
RESEARCH DESIGN AND
METHODS
Study population
We derived the data for our analyses from
the Sacramento Area Latino Study on
Aging (SALSA), a large representative
ongoing prospective cohort study of
community-dwelling Latinos in California.
Participants were 60–101 years of age at
baseline in 1998–1999. Trained bilingual
interviewers conducted in-home inter-
views covering sociodemographics, life-
style factors, and medical diagnoses. A
fasting blood sample was drawn on the
day of the interview. A previous publica-
tion describes further details of the survey
and cohort design (14). At baseline recruit-
ment, 1,789 people were enrolled in the
study. We excluded 523 participants with-
out measures of antibody titers to HSV1,
VZV,CMV,T. gondii, orH. pylori at baseline
and an additional 69 without measures of
other covariates of interest at baseline.
There were more males and older individ-
uals in the excluded group compared with
those not excluded (71.8 vs. 68.8 years, P
, 0.0001; 47 vs. 39% male, P = 0.0009),
whereas incident rates of diabetes were not
significantly different (3.09 vs. 2.95 per
100 person-years, P = 0.77). To determine
factors related to incident diabetes, we fur-
ther excluded 411 participantswho already
had diabetes at baseline and 4 individuals
without follow-up after baseline. There-
fore, our study subsample comprised 782
individuals who were diabetes-free at base-
line. The SALSA cohort was approved by
the institutional review boards at the
University of Michigan and the University
of California, San Francisco and Davis.
Outcome ascertainment
Follow-up data on diabetes were available
through June 2008, with a total of 144
incident diabetes events. We defined in-
cident diabetes as meeting any of the
following criteria in semiannual follow-
up interviews or annual laboratory ex-
aminations: 1) self-report of a physician’s
diagnosis of diabetes, 2) fasting blood
glucose level of $126 mg/dL, 3) usage
of diabetes medication (insulin or oral
hypoglycemic agent), or 4) diabetes listed
as a cause of death anywhere on a death
certificate. Age at incident diabetes was
computed by adding enrollment age
and years of follow-up from recruitment
to earliest evidence of diabetes according
to the above criteria. Individuals without
any evidence of diabetes were censored at
the time of the last visit or death because
of causes other than diabetes.
Covariates
Socioeconomic status was determined by
the years of formal education received. In-
come was not used because many of these
individuals were retired; therefore, income
was unlikely to provide a sensitive measure
of lifetime socioeconomic status. Place of
birth was defined as having been born in
the U.S. or Mexico or another Latin Amer-
ican country. BMIwasmeasured at baseline
and computed by weight in kilograms
divided by height in meters squared. Waist
and hip measurements were taken at base-
line in inches, and waist-to-hip ratio was
determined by dividing the waist measure-
ments by the hip measurements. Smokers
were categorized into never-smokers, for-
mer smokers, and current smokers. Pres-
ence of vascular disease was determined
by a self-report of a physician’s diagnosis of
heart attack, chest paindue toheart disease,
congestive heart failure, intermittent clau-
dication, stroke, irregular heart rhythm,
deep vein thrombosis, or coronary/heart
catheterization. Systolic and diastolic blood
pressures were measured at baseline and in
annual follow-up visits in sitting position.
Medications for diabetes were determined
by a medicine cabinet inventory by a
trained interviewer at the baseline and an-
nual interviews.
Laboratory analysis
Measurement of IL-6, CRP, HDL, LDL,
glucose, and insulin levels in serum taken
from fasting blood samples took place at
University of Michigan. IL-6 levels were
determined using the Quantiglo Chemi-
luminsecent Immunoassay (QTA00B and
Q6000B, respectively; R&D Systems,
Minneapolis, MN). CRP levels were as-
sayed with the CRP Ultra Wide Range Re-
agent Kit latex-enhanced immunoassay
(Equal Diagnostics, Exton, PA). Morning
fasting blood samples were used to mea-
sure LDL and HDL cholesterol levels.
HDL cholesterol was measured directly
using the HDL Direct reagent (number
3034569; Roche Diagnostics, Indianapo-
lis, IN). LDL cholesterol levels were de-
termined by LDL Direct Liquid Select
(number 7120; Equal Diagnostics). Glu-
cose was measured by the Cobas Mira
Chemistry Analyzer (Roche Diagnostics).
Insulin levels were measured using a
double-antibody radioimmunoassay us-
ing a 125I-human insulin tracer (Linco
Research, Charles, MO), a guinea pig
anti-porcine insulinfirst antibody (Michigan
Diabetes Research and Training Center,
68.5% cross-reaction to human pro-
insulin), and a goat anti–guinea pig
gammaglobulin-polyethylene glycol sec-
ond antibody (Antibodies Inc., Davis, CA)
and standardized against the Human Insu-
lin International Reference Preparation
(National Institute for Biological Standards
and Control). Homeostatic model assess-
ment for insulin resistance (HOMA-IR)
was computed by taking the product of
the fasting glucose (milligrams per deci-
liter) and insulin values and dividing by
405. Frozen (2708C) serum samples
were sent to the Stanley Laboratory of
Developmental Neurovirology at the
Johns Hopkins University to measure
antibody titers to HSV1, VZV, CMV,
T. gondii, and H. pylori. A solid-phase en-
zyme-linked immunosorbent assay was
used for detecting type-specific IgG anti-
body responses to the infectious agents
measured by optical density units, as pre-
viously described (15).
Statistical analysis
The distributions of baseline covariates
were compared across diabetes status by
using x2 tests for categorical variables and
Wilcoxon rank-sum test for continuous
variables. Participants were considered
seropositive for a specific infection if the
measured antibody titer levels were $1
optical density unit. To determine sensi-
tivity of results to the optical density
threshold, we also performed the analysis
defining seropositivity as having optical
density units $1.1. We performed Cox
proportional hazards models to quantify
the relative hazard of diabetes between
pathogen profiles among individuals
without diabetes at baseline using age at
diabetes diagnosis as the time scale. Two
proportional hazards models were con-
structed: 1) sex- and education-adjusted
analysis and 2) multivariate analysis with
sex, education, and covariates associated
with incident diabetes rate in model 1 at
significance levels of P , 0.20. The mul-
tivariate models included sex, education,
and smoking status as potential con-
founders because they are established
risk factors for both infection and diabe-
tes. Additional variables considered for
the multivariate model included vascular
disease, BMI, waist-to-hip ratio, diastolic
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and systolic blood pressure, and HDL
and LDL cholesterol, because obesity,
hypertension, and lipid profiles were
implicated in cardiometabolic disorders
and, if related to diabetes, could improve
the precision of the model. Because the
study population comprised elderly indi-
viduals, we further considered the poten-
tial for selection bias by performing a
competing risk model for all non–diabetes-
related deaths. We confirmed that pro-
portional hazards assumption was met
by testing the interaction between time
and the covariates included in the multi-
variate model.
Furthermore, HOMA-IR, IL-6, and
CRP were investigated as potential media-
tors, because they are known to be involved
in inflammatory or endocrine processes
that contribute to metabolic disorders. To
qualify as mediators, the markers of in-
flammation or insulin resistance had to
satisfy the Baron and Kenny (16) criteria of
mediation as follows: 1) pathogen seropos-
itivity is associated with the marker, 2) the
marker is associated with diabetes rate, and
3) controlling for the marker significantly
alters the association between pathogen se-
ropositivity and incident rate. All statistical
analyses were conducted in SAS 9.2 (SAS
Institute, Cary, NC).
RESULTSdAmong 782 diabetes-free
participants in the SALSA cohort with
information on baseline covariates, 144
individuals developed diabetes and 92
individuals died because of causes other
than diabetes during 4,886 person-years
of follow-up (incidence rate of diabetes of
2.95 per 100 person-years and incidence
rate of death of 1.88 per 100 person-years).
The median age of the study population
was 68.7 years, and 38% were male. There
was no difference by age, sex, and educa-
tion between individuals who had devel-
oped diabetes and individuals who had not
(Table 1). Individuals who developed dia-
betes were more likely to have a history of
vascular disease, have smoked in the past,
have lower HDL and LDL cholesterol lev-
els, and have higher glucose, insulin, and
HOMA-IR levels at baseline. Of 144 indi-
viduals who developed diabetes, 64 were
found to be taking diabetes medication
during follow-up. Seropositivity to HSV1,
VZV, CMV, and T. gondii was not signifi-
cantly different among individuals with
and without diabetes, whereas seropositiv-
ity to H. pylori was significantly greater
among individualswho developed diabetes
compared with nondiabetic individuals
(Table 1). The incidence rates of diabetes
among HSV1-, VZV-, CMV-, T. gondii–,
and H. pylori–infected individuals were
3.06, 2.92, 2.98, 2.97, and 3.10 per 100
person-years, respectively, whereas rates
among the seronegative individuals were
1.87, 2.97, 2.73, 2.93, and 1.22 cases per
100 person-years, respectively. Distribu-
tion of covariates by infection status is sum-
marized in Table 2.
In sex- and education-adjusted
model, those seropositive to HSV1 or H.
pylori were more likely to develop diabe-
tes at any given time than those who were
seronegative (hazard ratio [HR] for HSV1
1.61 [95%CI 0.82–3.17]; HR forH. pylori
2.42 [0.99–5.92]), but the effects did not
reach statistical significance. The estimate
for H. pylori became significant in a mul-
tivariate model (2.69 [1.10–6.60]), addi-
tionally adjusting for HSV1, vascular
disease, smoking, BMI, diastolic blood
pressure, and HDL and LDL cholesterol
levels (Table 3). Among individuals sero-
positive forH. pylori, 11% reported taking
medications for acid suppression, peptic
disorders, or antacids at baseline, and
0.8% were taking antibiotics used to treat
H. pylori infection (i.e., penicillin, macro-
lides, and tetracylines). Adjusting for
these medications did not affect the asso-
ciation between H. pylori and incident di-
abetes rate (multivariate HR for H. pylori
2.76 [1.12–6.81]). Furthermore, the re-
sults did not change in the sensitivity
analysis when we assigned a higher cutoff
to determine seropositivity to the infec-
tions (multivariate HR for H. pylori 3.14
[1.28–7.67]). Tests for interaction be-
tween covariates in the multivariate
model and time were not significant
when each interaction term was tested
separately, signifying that the propor-
tional hazards assumption was upheld.
Because H. pylori was the only pathogen
to reach statistical significance with inci-
dent diabetes rate in adjusted proportional
hazards models, we did not examine path-
ogen burden as an independent predictor
of incident diabetes rate.
Inclusion of HOMA-IR, CRP, and IL-6
in the model did not change the effect of
H. pylori (HR 2.72 [95% CI 1.11–6.68]).
Additionally, CRP and IL-6 were not as-
sociated with H. pylori, or with diabetes,
whereas HOMA-IR was associated with
increased rate of diabetes. Thus, HOMA-
IR, CRP, and IL-6 did not meet the three
Baron and Kenny criteria for mediation.
Table 1dSummary of characteristics by diabetes status in the SALSA cohort
No diabetes
(n = 638)
Incident diabetes
(n = 144) P
Infection
HSV1 571 (90) 135 (94) 0.12
VZV 231 (36) 52 (36) 0.98
CMV 561 (88) 127 (88) 0.93
T. gondii 226 (35) 50 (35) 0.87
H. pylori 580 (91) 139 (97) 0.03
Age (years) 69.0 (64.5–74.3) 67.9 (64.1–71.3) 0.03
Female 399 (63) 87 (60) 0.64
Education (years completed) 8 (3–12) 8 (3–12) 0.87
U.S. born 328 (51) 77 (53) 0.65
Vascular disease 172 (27) 60 (42) 0.0005
Smoking
Former smoker 242 (38) 75 (52) 0.005
Current smoker 82 (13) 11 (8)
BMI (kg/m2) 28.2 (25.1–31.6) 30.1 (27.2–33.3) ,0.0001
Waist-to-hip ratio 0.89 (0.84–0.95) 0.90 (0.84–0.95) 0.30
Diastolic blood pressure (mmHg) 76 (70–82) 76 (70–85) 0.21
Systolic blood pressure (mmHg) 136 (124–147) 138 (125–149) 0.55
HDL cholesterol (mg/dL) 52 (45–63) 49 (42–57) 0.004
LDL cholesterol (mg/dL) 127 (105–150) 119 (94–142) 0.009
Glucose (mg/dL) 91 (85–99) 105 (95–113) ,0.0001
Insulin (mIU/mL) 7.8 (5.1–12.1) 11.0 (7.4–15.8) ,0.0001
HOMA-IR 1.8 (1.1–2.8) 2.8 (1.8–4.2) ,0.0001
IL-6 (pg/mL) 3.4 (2.3–5.2) 3.8 (2.5–5.6) 0.06
CRP (mg/L) 3.1 (1.2–6.7) 3.8 (1.5–7.5) 0.09
Data are n (%) or median (interquartile range). n = 782.
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The multivariate model also showed
that participants with a history of vascular
disease (HR 1.78 [95% CI 1.27–2.50])
experienced higher incidence of diabetes
in multivariate analyses. BMI was posi-
tively associated with diabetes incidence
rate, whereas HDL and LDL were in-
versely associated (Table 3).
We considered the potential for se-
lection bias because of censoring of indi-
viduals who died from causes other than
diabetes. We found that individuals who
were smoking at baseline (HR 3.08 [95%
CI 1.70–5.58]) and individuals with vas-
cular disease (2.19 [1.41–3.40]) were
more likely to die from causes other
than diabetes during follow-up. On the
other hand, H. pylori was not associated
with deaths unrelated to diabetes (0.69
[0.31–1.54]) (Table 3).
CONCLUSIONSdIn this prospective
study of Latino elderly over 10 years, we
found that individuals seropositive for
H. pylori experienced a greater rate of in-
cident diabetes than individuals without
the infection. On the other hand, we did
not find a significantly increased rate of
incident diabetes in participants seroposi-
tive for HSV1, VZV, CMV, and T. gondii
compared with seronegative participants
and therefore did not examine whether
pathogen burden influenced the rate of in-
cident diabetes. Our finding on the effect
of H. pylori infection is in accord with the
results from previous studies by Gasbarrini
et al. (17) and So et al. (18), who found a
positive association between H. pylori in-
fection and the prevalence of diabetes in
cross-sectional studies. A cross-sectional
analysis of the baseline data from the
SALSA cohort also showed greater pre-
valence of diabetes in H. pylori–infected
individuals (data not shown). Our results
stand in contrast to several other cross-
sectional studies that found a lack of asso-
ciation between H. pylori and prevalence
of diabetes (13,19,20). We overcome
methodological limitations of previous
cross-sectional studies by examining the
impact of H. pylori infection on develop-
ment of diabetes over a 10-year follow-
up period. Thus, we were able to establish
the relative timing of seropositivity
and development of diabetes, giving
more credence to a potential causal re-
lationship. Furthermore, our study con-
trolled for multiple factors, including
age, sex, ethnicity, education, and car-
diometabolic risk factors by design and
analysis, thereby minimizing bias due to
confounding.
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–4.2)
3.5
(2.3
–5.3)
C
R
P
(m
g/L)
3.3
(0.95
–7.2)
3.1
(1.3
–6.8)
2.9
(1.2
–6.5)
3.3
(1.3
–7.4)
3.2
(1.2
–5.2)
3.1
(1.3
–7.0)
3.1
(1.2
–6.8)
3.1
(1.3
–7.1)
2.4
(1.3
–5.3)
3.1
(1.2
–6.9)
D
ata
are
n
(%
)
or
m
edian
(interquartile
range).n
=
782.*D
ifference
in
distribution
ofcorresponding
covariate
betw
een
seropositive
and
seronegative
in
dividuals
at
significan
ce
of
P
,
0.05.
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The mechanism by which H. pylori
infection increases the risk of diabetes re-
mains to be elucidated but may involve
inflammation or dyspepsia. Infection
withH. pyloriwas found in previous stud-
ies to be correlated with elevated levels
of CRP (21), IL-6, and tumor necrosis
factor-a (22), which are markers of inflam-
mation implicated in insulin resistance
and development of diabetes (8). Further-
more, the presence of Gram-negative
bacteria, such as H. pylori, in the gut mi-
crobiota leads to increased production of
lipopolysaccharide, which also activates
innate inflammatory processes (9). The
inflammation hypothesis, however, was
not substantiated in our analysis, since
we could not establish that IL-6 and
CRP levels were elevated in H. pylori se-
ropositive individuals or in those who de-
veloped diabetes. The fact that other
pathogens associated with systemic in-
flammation such as HSV and CMV were
not associated with diabetes, as had been
found in a previous study on the associ-
ation between pathogen burden and di-
abetes (13), casts some doubt on the role
the inflammation. An alternative hypoth-
esis is that gastroduodenal conditions re-
sulting from H. pylori infection could
delay gastric emptying (23), which has
been postulated to cause poor glucose
control in insulin-dependent children
with diabetes (24). The biological impact
of H. pylori–associated disorders on glu-
cose metabolism and insulin sensitivity
should be further investigated.
In addition to our finding for H. pylori,
we found that HDLwas inversely associated
with diabetes, whereas BMI, diastolic blood
pressure, and vascular disease were posi-
tively associatedwith diabetes, which is con-
sistent with the current understanding of
risk factors for diabetes, such as low HDL,
obesity, hypertension, and history of CVD
(25). Our finding for LDL was unexpected;
however, this phenomenon has been ob-
served previously (26), and high LDL is
not an established risk factor for diabetes.
Our study was limited by a number of
factors that would be ameliorated by
conducting similar studies in other more
diverse populations. First, only a small
percentage of the population was sero-
negative for H. pylori (7%) and HSV1
(10%), which limited the power of the
study and increased the width of our con-
fidence intervals. Our study had 16–
19% power to detect an HR of 1.25,
40–47% power to detect an HR of 1.50,
77–85% power to detect an HR of 2.00,
and 92–96% power to detect an HR of
2.50 given the distribution of HSV1 and
H. pylori seropositivity in the study.Despite
the low power, it is possible that our find-
ing for H. pylori may have resulted from
chance given the small sample of seroneg-
ative individuals. In addition, we could not
distinguish recent versus historic H. py-
lori infection. However, a U.S. popula-
tion-based study of H. pylori has shown
that 63% of Hispanics are infected by the
age of 60 years (27). Very few participants
in the SALSA cohort were taking a proton
pump inhibitor or antibiotics used to treat
H. pylori at baseline. Thus, treatment for
recent infection is unlikely, and most of
these elderly individuals have probably
been infected before enrollment without
overt symptoms. Our finding may not be
generalizable to younger individuals con-
sidering that they have a shorter history
of infection. Future studies should consider
investigating a younger population among
whom acquisition of H. pylori infection ac-
tively occurs. Furthermore, because this was
an observational study, there is potential
for confounding by factors such as diet
and family history of diabetes that may be
linked to vulnerability to infection and
Table 3dSummary of associations with incident diabetes and death due to other causes in the SALSA cohort
HR (95% CI) for diabetes HR (95% CI) for death due to other causes
Sex and education
adjusted
Multivariate
analysis*
Sex and education
adjusted
Multivariate
analysis*
Infection
HSV1 1.61 (0.82–3.17) 1.46 (0.74–2.89) 1.05 (0.52–2.11) 1.42 (0.69–2.90)
VZV 0.98 (0.70–1.38) NA 0.87 (0.57–1.34) NA
CMV 1.08 (0.64–1.82) NA 1.68 (0.67–4.21) NA
T. gondii 0.97 (0.69–1.37) NA 0.96 (0.61–1.51) NA
H. pylori 2.42 (0.99–5.92) 2.69 (1.10–6.60) 0.90 (0.42–1.96) 0.69 (0.31–1.54)
Female 0.88 (0.62–1.23) 1.12 (0.76–1.66) 0.84 (0.55–1.29) 0.80 (0.49–1.29)
Education (1-year increase) 0.99 (0.96–1.02) 1.00 (0.97–1.03) 1.00 (0.96–1.05) 1.01 (0.96–1.05)
U.S. born 1.16 (0.80–1.69) NA 0.78 (0.50–1.22) NA
Vascular disease 1.86 (1.33–2.59) 1.78 (1.27–2.50) 2.16 (1.42–3.29) 2.19 (1.41–3.40)
Smoking (compared with never smokers)
Former smoker 1.53 (1.06–2.22) 1.34 (0.93–1.93) 1.00 (0.61–1.66) 0.93 (0.55–1.58)
Current smoker 0.82 (0.42–1.59) 0.81 (0.41–1.59) 3.13 (1.78–5.53) 3.08 (1.70–5.58)
BMI (1-unit increase) 1.05 (1.02–1.07) 1.03 (1.00–1.06) 0.96 (0.92–1.01) 0.99 (0.95–1.04)
Waist-to-hip ratio (0.1-unit increase) 1.06 (0.86–1.30) NA 1.00 (0.78–1.28) NA
Diastolic blood pressure (10 mmHg increase) 1.12 (0.94–1.33) 1.12 (0.95–1.34) 0.84 (0.68–1.04) 0.92 (0.74–1.14)
Systolic blood pressure (10 mmHg increase) 1.03 (0.94–1.13) NA 1.01 (0.91–1.12) NA
HDL cholesterol (10 mg/dL increase) 0.81 (0.70–0.93) 0.86 (0.74–0.99) 1.07 (0.92–1.25) 1.10 (0.94–1.28)
LDL cholesterol (10 mg/dL increase) 0.93 (0.88–0.97) 0.95 (0.90–1.00) 0.96 (0.90–1.02) 0.96 (0.90–1.03)
HOMA-IR (1-unit increase) 1.24 (1.18–1.32) NA 0.99 (0.88–1.11) NA
IL-6 (10 pg/mL increase) 1.18 (0.90–1.56) NA 1.64 (1.21–2.23) NA
CRP (10 mg/L increase) 1.09 (0.90–1.32) NA 1.39 (1.20–1.61) NA
NA, value not applicable, since corresponding covariates were not included in themultivariate model. *Multivariate analyses include sex, education, and any variables
associatedwith diabetes in the sex- and education-adjustedmodel atP, 0.20, with the exception ofHOMA-IR, IL-6, andCRP,whichwere considered asmediation factors.
524 DIABETES CARE, VOLUME 35, MARCH 2012 care.diabetesjournals.org
H. pylori and diabetes
diabetes. In addition, the inverse associa-
tion between age and diabetes indicate a
potential for survivor bias. In fact, results
from the competing risk model show that
individuals with vascular disease and who
smoked at baseline were more likely to die
from nondiabetes causes, indicating that
the surviving population was healthier.
However, we did not find that individuals
with a H. pylori infection were more likely
to die from nondiabetes causes. Thus, it is
unlikely that survivor bias affected our re-
sult for the association between H. pylori
and diabetes.
In conclusion, we found that serolog-
ical evidence of H. pylori infection was as-
sociated with an increased rate of incident
diabetes in a Latino elderly cohort. In-
flammatory cytokines (i.e., CRP and IL-6)
did not appear to mediate the effect. Larger
prospective studies investigating the im-
pact of H. pylori infection on diabetes
and corresponding mediating factors are
warranted. If H. pylori plays an etiological
role in the development of type 2 diabetes,
preventive measures such as increased hy-
giene and treatments such as antibiotics
and proton pump inhibitor combinations
for treatment of H. pylori should be ex-
plored as targets of intervention in high-
risk communities.
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